Can Biomarkers of Coagulation, Platelet Activation, and Inflammation Predict Venous Thromboembolism in Patients with Haematological Malignancies?
| Autor: | Mervat M. Mattar, Shereef Elmoamly, Alaa Afif, Maha F. Yacoub |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Male
medicine.medical_specialty medicine.medical_treatment Fibrinogen Gastroenterology 03 medical and health sciences 0302 clinical medicine Von Willebrand factor Thromboembolism Internal medicine Fibrinolysis medicine Humans Prospective Studies cardiovascular diseases Platelet activation Inflammation Prothrombin time medicine.diagnostic_test biology business.industry Incidence Incidence (epidemiology) Antithrombin Hematology General Medicine Middle Aged Platelet Activation equipment and supplies Hematologic Neoplasms 030220 oncology & carcinogenesis Erythrocyte sedimentation rate biology.protein Female business Biomarkers 030215 immunology medicine.drug |
| Zdroj: | Acta Haematologica. 141:245-253 |
| ISSN: | 1421-9662 0001-5792 |
| DOI: | 10.1159/000496914 |
| Popis: | Background: The incidence of venous thromboembolism (VTE) in haematological malignancies varies according to the type and grade of the disease and clinical variables, and there is a need to develop a tool to predict the occurrence of VTE in cancer patients at diagnosis to tailor prophylactic anticoagulation use during treatment. Objective: To study the incidence of VTE in haematological malignancies and clarify whether vascular and inflammatory biomarkers could be used as predictors of VTE in those patients. Methods: This was a prospective observational cohort study. Hypercoagulability and inflammatory biomarkers were assayed in a group of 171 patients with haematological malignancies at diagnosis. These markers included (1) coagulation and fibrinolysis activation markers (D-dimer, fibrinogen, antithrombin, plasminogen activator inhibitor 1), (2) endothelial and platelet activation markers (von Willebrand factor and soluble P-selectin), and (3) inflammatory markers (tumour necrosis factor αand interleukin 6). The end point was mortality or symptomatic VTE. Results/Conclusion: The incidence of symptomatic VTE was 7%. None of the tested biomarkers showed statistical significance as predictors for the occurrence of VTE in haematological malignancies. However, there were statistically significant associations between the occurrence of VTE and central venous access device insertion, the prothrombin time, and the erythrocyte sedimentation rate. An ESR above 106.5 mm/h is associated with increased VTE occurrence. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|